

**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

13<sup>th</sup> November, 2024

To,

<b>The Corporate Relationship Department</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

**Sub: Outcome of Board Meeting held on 13<sup>th</sup> November, 2024**

Dear Sir(s)/ Madam,

This is with reference to our earlier intimation dated 05<sup>th</sup> November, 2024, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), regarding holding of Board Meeting on Wednesday, 13<sup>th</sup> November, 2024 to *inter alia* approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2024.

The Board of Directors at its meeting held today, i.e. 13<sup>th</sup> November, 2024 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2024. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.00 p.m.

Request you to kindly take the same on record.

Sincerely,  
For Alkem Laboratories Limited

  
**Manish Narang**  
**President - Legal, Company Secretary & Compliance Officer**

Encl.: a/a

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended September 30, 2024 ("the Statement") which includes one branch of the Group located at Nepal being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information / financial results of five subsidiaries included in the consolidated unaudited financial results, whose interim financial information / financial results reflect total assets of Rs. 13,000.71 million as at September 30, 2024

**Deloitte  
Haskins & Sells LLP**

and, total revenues of Rs 4,339.29 million and Rs 7,970.69 million for the quarter and six months ended September 30, 2024 respectively, total net profit after tax of Rs 404.42 million and Rs. 745.72 million for the quarter and six months ended September 30, 2024 respectively and total comprehensive income of Rs 438.51 million and Rs 790.41 million for the quarter and six months ended September 30, 2024 respectively and net cash outflows of Rs. 945.14 million for the six months ended September 30, 2024, as considered in the Statement. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results includes the interim financial information of eighteen subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 11,791.44 million as at September 30, 2024 and, total revenue of Rs 1,892.68 million and Rs 3,603.18 million for the quarter and six months ended September 30, 2024 respectively, total profit after tax of Rs 139.59 million and Rs 124.67 million for the quarter and six months ended September 30, 2024 respectively and total comprehensive income of Rs 214.24 million and Rs 221.74 million for the quarter and six months ended September 30, 2024 respectively and net cash outflows of Rs. 554.39 million for the six months ended September 30, 2024, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

**Other Matter**

8. The comparative financial information of the Group for the quarter and six months ended September 30, 2023, for the quarter ended June 30, 2024 and for the year ended March 31, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed / audited, as applicable, by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information dated November 07, 2023, August 09, 2024 and May 29, 2024 respectively, expressed an unmodified conclusion / opinion, as applicable.

Our conclusion on the statement is not modified in respect of this matter.

h-

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Rupen K. Bhatt**  
Partner  
(Membership No. 046930)  
(UDIN: 240469308KEZZB3181 )

Place: Mumbai  
Date: November 13, 2024

**ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT**

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

<b>Sr No</b>	<b>Name of the component</b>	<b>Relationship</b>
1	Alkem Laboratories Limited	Parent
2	Alkem Laboratories Limited (Nepal Branch)	Branch
3	S&B Holdings S.a.r.l,	Wholly Owned Subsidiary
4	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary
5	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
6	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
7	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
8	Enzene Biosciences ltd, India	Subsidiary
9	Ascend Laboratories (PTY) ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Pvt ltd	Subsidiary
11	Indchemie Health Specialities Pvt ltd, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SON BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation. India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alixer Nexgen Therapeutics Limited (Incorporated on July 12, 2024)	Wholly Owned Subsidiary
30	Alkem Wellness Limited (incorporated on September 16, 2024)	Wholly Owned Subsidiary

*PH*

## ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

### Statement of Unaudited Consolidated Financial Results for the Quarter and Six months ended 30 September 2024

(₹ In Million except per share data)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
<b>1 Income</b>						
(a) Revenue from Operations	34,146.7	30,318.2	34,401.7	64,464.9	64,078.9	126,675.8
(b) Other Income	1,344.8	1,203.1	631.9	2,547.9	1,290.3	3,108.4
<b>Total Income</b>	<b>35,491.5</b>	<b>31,521.3</b>	<b>35,033.6</b>	<b>67,012.8</b>	<b>65,369.2</b>	<b>129,784.2</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	9,021.7	8,371.6	8,247.1	17,393.3	16,572.9	32,945.9
(b) Purchases of stock-in-trade	3,539.2	3,826.6	4,318.9	7,365.8	7,873.6	16,288.7
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(513.9)	(1,438.7)	704.7	(1,952.6)	809.9	141.2
(d) Employee benefits expense	6,104.9	6,022.7	5,553.8	12,127.6	11,230.3	22,010.1
(e) Finance costs	281.4	291.1	303.2	572.5	600.9	1,124.1
(f) Depreciation and amortisation expense	789.1	804.8	739.0	1,593.9	1,463.1	2,993.0
(g) Other expenses	8,466.5	7,449.6	8,109.9	15,916.1	16,233.0	32,835.0
<b>Total Expenses</b>	<b>27,688.9</b>	<b>25,327.7</b>	<b>27,976.6</b>	<b>53,016.6</b>	<b>54,783.7</b>	<b>108,338.0</b>
<b>3 Profit before exceptional items and tax (1) - (2)</b>	<b>7,802.6</b>	<b>6,193.6</b>	<b>7,057.0</b>	<b>13,996.2</b>	<b>10,585.5</b>	<b>21,446.2</b>
<b>4 Exceptional items (refer note 4)</b>	-	-	(576.6)	-	(576.6)	(1,214.9)
<b>5 Profit before tax (3) + (4)</b>	<b>7,802.6</b>	<b>6,193.6</b>	<b>6,480.4</b>	<b>13,996.2</b>	<b>10,008.9</b>	<b>20,231.3</b>
<b>6 Tax expense / (credit)</b>						
(a) Current tax	1,558.8	1,244.3	1,590.5	2,803.1	2,248.3	4,222.8
(b) Deferred tax	(775.8)	(553.1)	(1,259.0)	(1,328.9)	(1,266.4)	(2,106.1)
<b>Total Tax Expense (a + b)</b>	<b>783.0</b>	<b>691.2</b>	<b>331.5</b>	<b>1,474.2</b>	<b>981.9</b>	<b>2,116.7</b>
<b>7 Profit for the period (5) - (6)</b>	<b>7,019.6</b>	<b>5,502.4</b>	<b>6,148.9</b>	<b>12,522.0</b>	<b>9,027.0</b>	<b>18,114.6</b>
<b>8 Other Comprehensive Income (net of tax)</b>						
(a) (i) Items that will not be reclassified to profit or loss	(66.4)	(49.8)	(29.8)	(116.2)	(69.3)	(93.4)
(ii) Income tax relating to items that will not be reclassified to profit or loss	21.4	16.0	10.6	37.4	23.7	29.8
(b) (i) Items that will be reclassified to profit or loss	106.0	74.9	129.1	180.9	267.7	264.0
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other Comprehensive Income (net of tax)</b>	<b>61.0</b>	<b>41.1</b>	<b>109.9</b>	<b>102.1</b>	<b>222.1</b>	<b>200.4</b>
<b>9 Total Comprehensive Income for the period (7) + (8)</b>	<b>7,080.6</b>	<b>5,543.5</b>	<b>6,258.8</b>	<b>12,624.1</b>	<b>9,249.1</b>	<b>18,315.0</b>
<b>10 Profit attributable to</b>						
a) Owners of the Company	6,886.4	5,451.6	6,205.2	12,338.0	9,072.5	17,957.7
b) Non-Controlling Interest	133.2	50.8	(56.3)	184.0	(45.5)	156.9
<b>11 Other Comprehensive Income attributable to</b>						
a) Owners of the Company	68.5	44.1	111.8	112.6	228.7	206.5
b) Non-Controlling Interest	(7.5)	(3.0)	(1.9)	(10.5)	(6.6)	(6.1)
<b>12 Total Comprehensive Income attributable to</b>						
a) Owners of the Company	6,954.9	5,495.7	6,317.0	12,450.6	9,301.2	18,164.2
b) Non-Controlling Interest	125.7	47.8	(58.2)	173.5	(52.1)	150.8
<b>13 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>14 Other Equity</b>						<b>102,881.5</b>
<b>15 Earnings Per Share (not annualised)</b>						
(a) Basic (₹)	57.60	45.60	51.90	103.20	75.88	150.19
(b) Diluted (₹)	57.60	45.60	51.90	103.20	75.88	150.19

**Statement of Unaudited Consolidated Assets and Liabilities as at 30 September 2024**

(₹ in Million)

Particulars	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
<b>I. ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property, plant and equipment	20,128.5	21,614.6
(b) Right of use assets	2,564.2	2,471.7
(c) Capital work-in-progress	2,918.9	1,484.0
(d) Goodwill	4,192.0	4,167.4
(e) Other intangible assets	458.6	474.1
(f) Intangible assets under development	723.0	101.7
(g) Financial Assets		
(i) Other investments	8,234.3	3,348.0
(ii) Other financial assets	2,748.9	1,202.2
(h) Deferred tax assets (net)	16,532.6	15,148.3
(i) Other tax assets (net)	582.9	781.7
(j) Other non-current assets	993.6	839.5
<b>Total Non-current assets</b>	<b>60,077.5</b>	<b>51,633.2</b>
<b>2 Current assets</b>		
(a) Inventories	29,121.8	26,611.8
(b) Financial Assets		
(i) Investments	3,366.3	1,489.9
(ii) Trade receivables	24,981.1	22,528.1
(iii) Cash and cash equivalents	4,125.8	4,550.7
(iv) Bank balances other than (iii) above	15,396.7	11,242.8
(v) Loans	146.9	90.7
(vi) Other financial assets	24,507.6	29,302.0
(c) Other current assets	8,100.3	6,299.8
<b>Total Current assets</b>	<b>109,746.5</b>	<b>104,115.8</b>
<b>3 Assets held for sale</b>	1,346.3	-
<b>TOTAL ASSETS</b>	<b>171,170.3</b>	<b>155,749.0</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
(a) Equity share capital	239.1	239.1
(b) Other Equity	114,689.4	102,881.5
<b>Equity attributable to owners of the Company</b>	<b>114,928.5</b>	<b>103,120.6</b>
(c) Non-controlling interest	4,172.3	4,023.4
<b>Total Equity</b>	<b>119,100.8</b>	<b>107,144.0</b>
<b>2 Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,259.5	400.0
(ii) Lease liabilities	2,133.3	1,892.6
(iii) Other financial liabilities	3,488.2	3,109.9
(b) Provisions	3,173.6	2,998.6
(c) Other non-current liabilities	238.9	258.4
<b>Total Non-Current liabilities</b>	<b>10,293.5</b>	<b>8,659.5</b>
<b>3 Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	11,103.2	11,739.7
(ii) Lease liabilities	283.0	151.8
(iii) Trade payables		
Dues of Micro and Small Enterprises	647.4	670.0
Dues of Creditors other than Micro and Small Enterprises	18,215.1	16,811.2
(iv) Other financial liabilities	6,815.1	6,457.7
(b) Other current liabilities	2,293.5	2,296.6
(c) Provisions	1,493.1	1,268.7
(d) Current tax Liabilities (Net)	862.7	549.9
<b>Total Current liabilities</b>	<b>41,713.1</b>	<b>39,945.5</b>
<b>4 Liabilities classified as held for sale</b>	62.9	-
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>171,170.3</b>	<b>155,749.0</b>

**Statement of Unaudited Consolidated Cash flow for the period ended 30 September 2024**

(₹ in million)

Particulars	For the period ended 30 September 2024 (Unaudited)	For the period ended 30 September 2023 (Unaudited)
<b>A Cash Flow from Operating Activities:</b>		
Profit before Tax	13,996.2	10,008.9
<u>Adjustments for:</u>		
Depreciation and amortisation expense	1,593.9	1,463.1
Liabilities no longer required written back	(1.0)	-
Profit on sale of investments (net)	(0.9)	(24.1)
Unrealised (gain) / loss on fair valuation of investments (net)	(193.2)	(75.2)
Loss on sale / write off of property plant and equipment (net)	42.6	13.2
Employee stock compensation expenses	79.3	49.2
Unrealised foreign currency (gain) / loss on revaluation (net)	(141.0)	645.6
Dividend Income	(1.6)	(1.2)
Interest Income	(1,810.2)	(1,164.6)
Impairment loss on property, plant and equipment	17.5	576.6
Interest expenses	572.5	600.9
Provision for doubtful advances	11.7	-
Expected credit loss on receivables	76.1	328.4
Rent received	(3.6)	-
<b>Subtotal of Adjustments</b>	<b>242.1</b>	<b>2,411.9</b>
<b>Operating profit before working capital changes</b>	<b>14,238.3</b>	<b>12,420.8</b>
Adjustments for changes in working capital:		
(Increase) in trade receivables	(2,513.8)	(3,680.6)
Decrease/ (Increase) in loans, other financial assets and other assets	306.0	(762.4)
(Increase) / Decrease in inventories	(2,510.0)	542.8
Increase in trade payable, other financial liabilities and other liabilities	2,028.8	2,406.2
Increase in provisions	160.1	359.9
<b>Subtotal of adjustments</b>	<b>(2,528.9)</b>	<b>(1,134.1)</b>
<b>Cash generated from operations</b>	<b>11,709.4</b>	<b>11,286.7</b>
Less: Income taxes paid (net of refund)	(2,291.5)	(1,937.5)
<b>Net Cash generated from operating activities</b>	<b>9,417.9</b>	<b>9,349.2</b>
<b>B Cash Flow from Investing Activities:</b>		
Purchases of property, plant and equipment (including capital work in progress, other intangible assets and intangible assets under development)	(3,065.4)	(1,163.0)
Proceeds from disposal of property, plant and equipment	85.4	20.2
Investments made in fixed deposits	(16,585.3)	(6,298.0)
Redemption of fixed deposits	15,466.6	-
Investments in other than bank deposits	(6,730.0)	-
Redemption of investments other than bank deposits	161.3	66.3
Dividend received	1.6	1.2
Interest received	1,683.9	1,121.3
Rent received	3.6	-
<b>Net cash (used in) investing activities</b>	<b>(8,978.3)</b>	<b>(6,252.0)</b>
<b>C Cash Flow from Financing Activities:</b>		
Proceeds from non-current borrowings (net)	916.6	-
(Repayment of) / Proceeds from current borrowings (net)	(2,895.0)	(735.3)
Dividend paid	(622.3)	(1,220.2)
Principal repayment of lease liabilities	(188.6)	(162.3)
Interest paid	(420.7)	(499.4)
<b>Net cash (used in) financing activities</b>	<b>(3,210.0)</b>	<b>(2,617.2)</b>
<b>D Net (decrease)/increase in Cash and Cash Equivalents (A+B+C)</b>	<b>(2,770.4)</b>	<b>480.0</b>
<b>E Cash &amp; Cash Equivalents as at the beginning of the year</b>	<b>663.1</b>	<b>2,738.0</b>
Add/Less: Effect of exchange difference on foreign currency cash and cash equivalents	159.9	(9.8)
<b>F Cash &amp; Cash Equivalents as at the end of the period (D+E)</b>	<b>(1,947.4)</b>	<b>3,208.2</b>

**Notes:**

- Components of cash and cash equivalents for the purpose of Cash flow as per IND AS 7:

Cash and cash equivalents	4,125.8	3,208.2
Loans repayable on demand from banks	(6,073.2)	-
<b>Total cash and cash equivalents</b>	<b>(1,947.4)</b>	<b>3,208.2</b>
- The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - "Statement of Cash Flows".

**Notes to the Consolidated Financial results:**

- 1 The above unaudited consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'.
- 2 The above unaudited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 12 November 2024 and subsequently approved by the Board of Directors at its meeting held on 13 November 2024. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2024.
- 3 The comparative financial information of the Group for the quarter ended 30 June 2024, comparative quarter and six months ended 30 September 2023 and for the year ended 31 March 2024, prepared in accordance with Ind AS included in this statement have been reviewed/ audited by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information are dated 09 August 2024, 07 November 2023 and 29 May 2024 respectively.
- 4 Exceptional item for the quarter ended 30 September 2023 included impairment loss of ₹ 576.6 Million towards its plant located at St. Louis, USA.  
  
Exceptional items for the year ended 31 March 2024 included impairment loss of ₹ 576.6 Million and ₹ 415.6 Million towards its plant located at St. Louis, USA and Indore respectively and net loss of ₹ 222.7 Million (net of recovery) on account of cyber security.  
  
In the current quarter ended 30 September 2024, the Parent Company as part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently, related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale.
- 5 As approved by the Members of the Parent Company at the Annual General Meeting held on 30 August 2024, the Company has disbursed a final dividend of ₹ 5 (Rupees Five Only) per equity share (face value of ₹ 2 each).
- 6 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

Place: Mumbai  
Date: 13 November 2024

By Order of the Board  
For Alkem Laboratories Limited

  
B.N. Singh  
Executive Chairman  
DIN: 00760310

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal, for the quarter and six months ended September 30, 2024, ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Other Matter**

5. The comparative financial information of the Company for the quarter and six months ended September 30, 2023, for the quarter ended June 30, 2024 and for the year ended March 31, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed / audited, as applicable, by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information dated November 07, 2023, August 09, 2024 and May 29, 2024 respectively, expressed an unmodified conclusion / opinion, as applicable.

Our conclusion on the statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Rupen K. Bhatt**  
(Partner)  
(Membership No. 046930)  
(UDIN: 24046930BKEZZA9692 )

Place: Mumbai  
Date: November 13, 2024



**ALKEM LABORATORIES LIMITED**

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.  
Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190  
Website : www.alkemlabs.com, Email id : investors@alkem.com

**Statement of Unaudited Standalone Financial Results for the Quarter and Six months ended 30 September 2024**

(₹ in Million except per share data)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
<b>1 Income</b>						
(a) Revenue from Operations	28,719.7	25,001.0	26,345.9	53,720.7	48,877.6	97,477.2
(b) Other Income	1,201.9	1,061.0	618.4	2,282.9	1,265.4	3,059.9
<b>Total Income</b>	<b>29,921.6</b>	<b>26,062.0</b>	<b>26,964.3</b>	<b>55,983.6</b>	<b>50,143.0</b>	<b>100,537.1</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	7,322.9	7,612.3	7,071.2	14,935.2	13,964.9	27,499.3
(b) Purchases of stock-in-trade	3,154.0	2,073.6	2,823.9	5,227.6	5,275.6	11,287.0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	393.7	(856.6)	106.6	(462.9)	(525.7)	(713.1)
(d) Employee benefits expense	4,297.6	4,259.0	3,951.8	8,556.6	8,092.4	15,602.8
(e) Finance costs	175.7	214.4	187.0	390.1	401.2	819.1
(f) Depreciation and amortisation expense	625.8	643.5	590.2	1,269.4	1,171.3	2,443.5
(g) Other expenses	6,275.1	5,706.4	5,846.4	11,981.5	12,186.9	24,149.9
<b>Total Expenses</b>	<b>22,244.9</b>	<b>19,652.6</b>	<b>20,577.1</b>	<b>41,897.5</b>	<b>40,566.6</b>	<b>81,088.5</b>
<b>3 Profit before exceptional items and tax (1) - (2)</b>	<b>7,676.7</b>	<b>6,409.4</b>	<b>6,387.2</b>	<b>14,086.1</b>	<b>9,576.4</b>	<b>19,448.6</b>
<b>4 Exceptional items (refer note 4)</b>	-	-	-	-	-	(638.3)
<b>5 Profit before tax (3) + (4)</b>	<b>7,676.7</b>	<b>6,409.4</b>	<b>6,387.2</b>	<b>14,086.1</b>	<b>9,576.4</b>	<b>18,810.3</b>
<b>6 Tax expense / (credit)</b>						
(a) Current tax	1,323.2	1,112.6	1,114.8	2,435.8	1,654.1	3,332.8
(b) Deferred tax	(622.3)	(535.7)	(1,192.7)	(1,158.0)	(1,257.2)	(1,994.0)
<b>Total Tax expense / (credit) (a + b)</b>	<b>700.9</b>	<b>576.9</b>	<b>(77.9)</b>	<b>1,277.8</b>	<b>396.9</b>	<b>1,338.8</b>
<b>7 Profit for the period after tax (5 - 6)</b>	<b>6,975.8</b>	<b>5,832.5</b>	<b>6,465.1</b>	<b>12,808.3</b>	<b>9,179.5</b>	<b>17,471.5</b>
<b>8 Other Comprehensive Income (net of tax)</b>						
(a) (i) Items that will not be reclassified to profit or loss	(38.3)	(38.2)	(24.1)	(76.5)	(48.2)	(66.8)
(ii) Income tax relating to items that will not be reclassified to profit or loss	13.3	13.4	8.4	26.7	16.8	23.3
(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other Comprehensive Income (net of tax)</b>	<b>(25.0)</b>	<b>(24.8)</b>	<b>(15.7)</b>	<b>(49.8)</b>	<b>(31.4)</b>	<b>(43.5)</b>
<b>9 Total Comprehensive Income for the period (7) + (8)</b>	<b>6,950.8</b>	<b>5,807.7</b>	<b>6,449.4</b>	<b>12,758.5</b>	<b>9,148.1</b>	<b>17,428.0</b>
<b>10 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>11 Other Equity</b>						<b>105,307.0</b>
<b>12 Earnings Per Share (not annualised)</b>						
(a) Basic (₹)	58.34	48.78	54.07	107.12	76.77	146.13
(b) Diluted (₹)	58.34	48.78	54.07	107.12	76.77	146.13

**Statement of Unaudited Standalone Assets and Liabilities as at 30 September 2024**

(₹ in Million)

Particulars	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
<b>I. ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property, plant and equipment	14,984.2	16,596.7
(b) Right of use assets	910.0	879.6
(c) Capital work-in-progress	655.1	499.3
(d) Other intangible assets	311.9	346.1
(e) Intangible assets under development	408.5	408.5
(f) Financial Assets		
(i) Investment in subsidiaries	27,511.4	25,502.6
(ii) Other Investments	6,021.0	1,349.6
(iii) Loans	3.6	3.5
(iv) Other financial assets	2,381.1	520.6
(h) Deferred tax assets (net)	14,051.2	12,866.6
(i) Other tax assets (net)	202.9	492.2
(j) Other non-current assets	739.1	511.9
<b>Total Non-current assets</b>	<b>68,180.0</b>	<b>59,977.2</b>
<b>2 Current assets</b>		
(a) Inventories	19,167.0	18,495.6
(b) Financial Assets		
(i) Investments	3,301.2	1,437.6
(ii) Trade receivables	18,273.9	17,536.4
(iii) Cash and cash equivalents	688.4	389.5
(iv) Bank balances other than (iii) above	12,150.0	10,269.0
(v) Loans	32.3	39.5
(vi) Other financial assets	21,544.5	25,414.6
(c) Other current assets	6,570.2	6,818.6
<b>Total Current assets</b>	<b>81,727.5</b>	<b>80,400.8</b>
<b>3 Assets held for sale</b>	1,346.3	-
<b>TOTAL ASSETS</b>	<b>151,253.8</b>	<b>140,378.0</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
(a) Equity share capital	239.1	239.1
(b) Other Equity	117,467.6	105,307.0
<b>Total Equity</b>	<b>117,706.7</b>	<b>105,546.1</b>
<b>2 Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Lease liabilities	499.2	376.0
(ii) Other financial liabilities	921.7	690.6
(b) Provisions	2,565.0	2,455.8
(c) Other non-current liabilities	226.9	245.5
<b>Total Non-Current liabilities</b>	<b>4,212.8</b>	<b>3,767.9</b>
<b>3 Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	5,073.4	9,572.3
(ii) Lease liabilities	193.1	103.8
(iii) Trade payables		
Dues of Micro and Small Enterprises	537.7	587.6
Dues of creditors other than Micro and Small Enterprises	16,770.7	15,121.8
(iv) Other financial liabilities	3,744.0	3,379.9
(b) Other current liabilities	1,023.5	1,192.2
(c) Provisions	1,270.0	1,106.4
(d) Current tax Liabilities (Net)	659.0	-
<b>Total Current liabilities</b>	<b>29,271.4</b>	<b>31,064.0</b>
<b>4 Liabilities classified as held for sale</b>	62.9	-
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>151,253.8</b>	<b>140,378.0</b>

**Statement of Unaudited Standalone Cash Flow for the period ended 30 September 2024**

(₹ in million)

Particulars	For six months ended 30 September 2024 (Unaudited)	For six months ended 30 September 2023 (Unaudited)
<b>A. Cash Flow from Operating Activities:</b>		
Profit before tax	14,086.1	9,576.4
<b>Adjustments for:</b>		
Depreciation and amortisation expense	1,269.4	1,171.3
Impairment loss on property, plant and equipment	17.5	-
Unrealised gain on fair valuation of investments (net)	(192.0)	(74.8)
Loss/ (profit) on sale of investments (net)	3.9	(19.3)
Loss on sale / write off of property plant and equipment (net)	42.9	14.0
Dividend income	(26.1)	(26.1)
Provision for doubtful advances	11.7	-
Interest income	(1,511.8)	(942.0)
Interest expenses	390.1	401.2
Expected credit loss on receivables	71.3	257.6
Rental income	(13.6)	-
Unrealised foreign currency (gain) / loss on revaluation (net)	(88.4)	403.9
<b>Subtotal of Adjustments</b>	<b>(25.1)</b>	<b>1,185.8</b>
<b>Operating profit before working capital changes</b>	<b>14,061.0</b>	<b>10,762.2</b>
<b>Adjustments for changes in working capital:</b>		
(Increase) / Decrease in trade receivables	(805.1)	511.7
(Increase) / Decrease in loans, other financial assets and other assets	340.7	(420.6)
Increase in inventories	(671.4)	(559.8)
Increase in trade payable, other financial liabilities and other liabilities	2,057.7	1,863.3
Increase in provisions	88.6	77.7
<b>Subtotal of Adjustments</b>	<b>1,010.5</b>	<b>1,472.3</b>
<b>Cash generated from operations</b>	<b>15,071.5</b>	<b>12,234.5</b>
Less: Income taxes paid (net of refund)	(1,487.4)	(1,643.4)
<b>Net cash generated from operating activities</b>	<b>13,584.1</b>	<b>10,591.1</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchases of property, plant and equipment (including capital work in progress, other intangible assets and intangible assets under development)	(1,041.2)	(609.5)
Proceeds from disposal of property, plant and equipment	69.3	16.1
Investments in subsidiaries	(2,008.9)	-
Investments made in fixed deposits	(14,939.4)	(6,119.6)
Redemption of fixed deposits	15,032.2	-
Investments in other than bank deposits	(6,397.0)	-
Redemption of investments other than bank deposits	108.0	130.4
Dividend received	26.1	26.1
Interest received	1,288.7	899.5
Rent received	13.6	-
<b>Net cash used in investing activities</b>	<b>(7,848.6)</b>	<b>(5,657.0)</b>
<b>C. Cash Flow from Financing Activities:</b>		
Repayment of current borrowings (net)	(2,806.3)	(3,231.5)
Principal repayment of lease liabilities	(99.1)	(72.4)
Dividend paid	(597.8)	(1,195.7)
Interest paid	(256.6)	(302.3)
<b>Net cash used in financing activities</b>	<b>(3,759.8)</b>	<b>(4,801.9)</b>
<b>D Net increase in cash and cash equivalents (A+B+C)</b>	<b>1,975.7</b>	<b>132.2</b>
<b>E Cash and cash equivalents as at beginning of the year</b>	<b>(1,330.7)</b>	<b>50.1</b>
<b>F Cash and cash equivalents as at end of the period (D+E)</b>	<b>645.0</b>	<b>182.3</b>

**Notes:**

**1 Components of cash and cash equivalents for the purpose of Cash flow as per IND AS 7:**

Cash and cash equivalents	688.4	182.3
Loans repayable on demand from banks	(43.4)	-
<b>Total cash and cash equivalents</b>	<b>645.0</b>	<b>182.3</b>

**2 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows"**

**Notes to the Standalone Financial results:**

- 1 The above unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 12 November 2024 and subsequently approved by the Board of Directors at its meeting held on 13 November 2024. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2024.
- 3 The comparative financial information of the Company for the quarter ended 30 June 2024, comparative quarter and six months ended 30 September 2023 and for the year ended 31 March 2024, prepared in accordance with Ind AS included in this statement have been reviewed/ audited by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information are dated 09 August 2024, 07 November 2023 and 29 May 2024 respectively.
- 4 Exceptional items for the year ended 31 March 2024 includes impairment loss of ₹ 415.6 Million towards its plant located at Indore and net loss of ₹ 222.7 Million (net of recovery) on account of cyber security. In the current quarter ended 30 September 2024, the Company as a part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently, related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale.
- 5 As approved by the Members of the Company at the Annual General Meeting held on 30 August 2024, the Company has disbursed a final dividend of ₹ 5 (Rupees Five Only) per equity share (face value of ₹ 2 each).
- 6 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

Place: Mumbai  
Date: 13 November 2024

By Order of the Board  
For Alkem Laboratories Limited



B.N. Singh  
Executive Chairman  
DIN: 00760310